Staying out of the sun in the summer is a smart move for your patients when it comes to skin protection. But less time in the sun means the body produces less vitamin D, which can cause a host of other issues.
This seasonal shift creates an opportunity for doctors to protect their patients’ health through targeted supplementation. Pellecome offers pharmaceutical-grade DHEA and vitamin K2/D3, available exclusively through licensed providers across the U.S. Backed by the expertise of Dr. Enrique Jacome, these supplements are formulated to support hormone balance, bone health, and treatment continuity in patients with limited sun exposure.
Limited UV Exposure and Nutrient Deficiency
When patients avoid the sun out of necessity, their ability to synthesize vitamin D from UVB light drops significantly. This drop can affect calcium absorption, weaken bone density, and impair immune regulation.1
For patients already dealing with hormone imbalance, this deficiency can add another layer of complication to treatment plans. DHEA levels may also decline with age and stress, and insufficient vitamin D could further influence hormone metabolism.2
How DHEA + K2/D3 Supplements Support Your Treatment Plan
DHEA is a precursor hormone that supports adrenal health, bone density, sexual function, and emotional well-being. Its role in postmenopausal bone health and general wellness has been studied in a variety of clinical contexts.3,4
Vitamin D3 promotes the absorption of calcium and phosphorus, both essential to skeletal health.5 Vitamin K2 works alongside D3 to guide calcium into the bones and away from soft tissues, while also contributing to healthy nerve function.6 The combination of D3 and K2 has shown promise in supporting cardiovascular and skeletal health.
Healthcare providers may consider incorporating these supplements into treatment plans to offer extra support for their patients.
Why Pellecome Stands Out for Providers
Pellecome’s DHEA and K2/D3 products are formulated for clinical use, using ingredients that meet the highest standards for safety and purity. These supplements are only available through licensed providers.
For providers already using Pellecome’s Re3 Advanced Pellet Delivery System, this trio of supplements adds another layer of support for hormone therapy, particularly for patients with limited sun exposure. And with no contracts or procedural fees, our platform makes it simple to expand your treatment offerings without additional burden.
To learn more about adding Pellecome’s DHEA and K2/D3 supplements to your practice or becoming a Pellecome provider, contact us at 888-773-9969.
- Wacker M, Holick MF. Sunlight and Vitamin D: A global perspective for health: A global perspective for health. Dermatoendocrinol [Internet]. 2013;5(1):51–108. Available from: http://dx.doi.org/10.4161/derm.24494
- Samaras N, Samaras D, Frangos E, Forster A, Philippe J. A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial? Rejuvenation Res [Internet]. 2013;16(4):285–94. Available from: http://dx.doi.org/10.1089/rej.2013.1425
- Ghebre MA, Hart DJ, Hakim AJ, Kato BS, Thompson V, Arden NK, et al. Association between DHEAS and bone loss in postmenopausal women: a 15-year longitudinal population-based study. Calcif Tissue Int [Internet]. 2011;89(4):295–302. Available from: http://dx.doi.org/10.1007/s00223-011-9518-9
- Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) [Internet]. 1998;49(4):421–32. Available from: http://dx.doi.org/10.1046/j.1365-2265.1998.00507.x
- Chu C, Tsuprykov O, Chen X, Elitok S, Krämer BK, Hocher B. Relationship between vitamin D and hormones important for human fertility in reproductive-aged women. Front Endocrinol (Lausanne) [Internet]. 2021;12:666687. Available from: http://dx.doi.org/10.3389/fendo.2021.666687
- Ushiroyama T, Ikeda A, Ueki M. Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas [Internet]. 2002;41(3):211–21. Available from: http://dx.doi.org/10.1016/s0378-5122(01)00275-4
